Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Benzinga
Published Mar 07, 2024 19:52
Updated Mar 07, 2024 21:10
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Benzinga - by Vandana Singh, Benzinga Editor.
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner.
ddBCMA (aka anito-cel) is Arcellx’s lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.
Also Read: Blood Cancer Player Arcellx Finds Place On Analyst Conviction List – Potential Room For Growth In 2024.
The domain’s differentiated design confers several advantages, including high transduction efficiency and stability, which drives a potential best-in-class profile and scalable manufacturability.
Morgan Stanley analysts model around $5 billion in unadjusted global peak ddBCMA sales across multiple treatment lines (vs. unadjusted global peak sales of around $8 billion for Carvykti per VA consensus) with a program blended probability of success (PoS) of 60% (higher in late-line, lower in earlier-line).
Carvykti (ciltacabtagene autoleucel) is marketed in collaboration between Johnson & Johnson (NYSE:JNJ) and Legend Biotech Inc (NASDAQ:LEGN).
Morgan Stanley initiates Arcellx with an Overweight rating with a price target of $81.
If ddBCMA proves successful, it could secure approval in the United States for late-line multiple myeloma by 2026, potentially capturing up to 46% of the market.
The promising Phase 2 data suggests that ddBCMA’s safety and efficacy profile is superior, positioning it to outperform Bristol-Myers Squibb Co (NYSE:BMY) and 2Seventy Bio Inc’s (NASDAQ:TSVT) Abecma (idecabtagene vicleucel) and compete effectively with Carvykti.
Collaborating with Gilead Sciences Inc (NASDAQ:GILD) is expected to provide Arcellx with valuable expertise in CAR-T cell manufacturing, helping avoid the manufacturing challenges that hindered Carvykti’s market reach.
In December 2023, Arcellx announced new data from its Phase 1 expansion study of CART-ddBCMA for relapsed and/or refractory multiple myeloma.
The interim anito-cel Phase 1 clinical results (October 15, 2023 cutoff date) demonstrate deep and durable responses.
Price Action: ACLX shares are down 2.08% at $71.43 on the last check Thursday.
Photo by Christina Victoria Craft on Unsplash
Latest Ratings for ACLX
| Mar 2022 | SVB Leerink | Initiates Coverage On | Outperform | |
| Mar 2022 | B of A Securities | Initiates Coverage On | Buy |
Get The App
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.